Shortened Survival With Minimally Invasive Surgery for Cervical Cancer

Treatment for patients with early-stage cervical cancer most often includes radical hysterectomy, which is associated with cure in more than 80% of patients. In recent years, minimally invasive surgery (laparoscopic or robotic) has largely replaced laparotomy (open abdominal surgery) as the preferred surgical method due to a decrease surgical morbidity associated with less invasive procedures. […]

Read More

osimertinib-nsclc-primelines

Broad Activity of Lorlatinib in ALK-Positive Advanced NSCLC

About 3% to 5% of patients with advanced non-small cell lung cancer (NSCLC) harbor ALK rearrangements. For many years, crizotinib was the only first-line treatment choice for these patients. However, in recent years several second-generation ALK inhibitors, including alectinib, ceritinib and brigatinib, have shown better efficacy than crizotinib, particularly for patients with brain metastases, and […]

Read More

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer

Immunotherapy with PD-1 and PD-L1 inhibitors has become the standard of care for patients with advanced urothelial cancer who have progressed on or are ineligible for cisplatin-based therapy. The success of these agents in the metastatic setting has led to investigation in earlier stages of disease. For muscle-invasive bladder cancer (MIBC), the current standard of […]

Read More

Cisplatin Chemoradiation Remains Gold Standard for Low-Risk HPV+ SCCHN

The incidence of human papilloma virus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is increasing. Oropharyngeal squamous cell carcinoma is considered a distinctive disease from HPV-negative cancer and has a better prognosis. Currently, the treatment of oropharyngeal cancer without distant metastases is similar for both HPV-positive and HPV-negative disease, with concomitant cisplatin-based […]

Read More

First-Line Avelumab Plus Axitinib Outperforms Sunitinib in RCC

For many years, the standard front-line therapy for advanced renal cell carcinoma (RCC) with clear cell histology was single-agent treatment with a vascular endothelial growth factor (VEGF) targeting tyrosine kinase inhibitor (TKI). Recently, however; immunotherapy with the PD-1 inhibitor nivolumab in combination with the CTLA-4 inhibitor ipilimumab was approved for use in patients with intermediate- […]

Read More

Atezolizumab Combo, a New First-Line Option for Advanced NSCLC

For newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations, the standard of care for many years was platinum-doublet chemotherapy. Recently, however; immunotherapy with PD-1 inhibitor pembrolizumab, either alone (for patients with PD-L1 expression over 50%) or in combination with platinum-based chemotherapy were approved as new standard for first-line treatment […]

Read More

First-Line Pembrolizumab Superior to EXTREME in Metastatic SCCHN

For years, first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has been the combination of platinum chemotherapy, 5-fluorouracil (5-FU), and cetuximab followed by cetuximab maintenance, commonly known as the EXTREME regimen. This regimen is associated with an overall survival (OS) of about 10 months. It has substantial toxicity but is […]

Read More

Local RT Improves Survival in Low Metastatic Burden Prostate Cancer

Men with newly diagnosed, metastatic prostate cancer are typically treated with systemic therapy, including androgen deprivation therapy (ADT), and receive local therapy for symptom palliation if needed. However, retrospective data suggest that local radiotherapy to the primary tumor may have an impact on survival in metastatic prostate cancer and patients with better prognoses may benefit […]

Read More

First-Line Olaparib Maintenance New Standard for BRCAm Ovarian Cancer

Treatment for newly diagnosed advanced ovarian cancer most often includes cytoreductive surgery and platinum-based chemotherapy. While this combination is highly effective, most patients will relapse within three years. For recurrent platinum-sensitive ovarian cancer, maintenance with poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib, niraparib, and rucaparib is standard of care following platinum-based chemotherapy, based on substantial […]

Read More